FDA approval spurs launch of Lupin’s generic Clobex Spray

Press enter to search
Close search
Open Menu

FDA approval spurs launch of Lupin’s generic Clobex Spray

04/02/2018
The same week Lupin received approval from the Food and Drug Administration for its generic Clobex Spray (clobetasol propionate spray, 0.05%), the company launched the drug.

Baltimore-based Lupin’s generic Clobex Spray is a treatment for moderate-to-severe plaque psoriasis that affects up to 20% body surface area in patients ages 18 years old and older.

The product had a market size of roughly $30.5 million for the 12 months ended January 2018, according to IQVIA data.

Related Topics